For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
LPI (LP Information)' newest research report, the "RNAi for Therapeutic Industry Forecast" looks at past sales and reviews total world RNAi for Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected RNAi for Therapeutic sales for 2023 through 2029. With RNAi for Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi for Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global RNAi for Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNAi for Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global RNAi for Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi for Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi for Therapeutic.
The global RNAi for Therapeutic market size is projected to grow from US$ 172.2 million in 2022 to US$ 2288.1 million in 2029; it is expected to grow at a CAGR of 44.7% from 2023 to 2029.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of RNAi for Therapeutic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- siRNA
- miRNA
- shRNA
Segmentation by application
- Cancer
- Cardiovascular
- HBV
- Others
The below companies that are profiled
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Alnylam Pharmaceuticals
- Arbutus Biopharma (Tekmira)
- Arrowhead
- Dicerna Pharmaceuticals
- Mirna Therapeutics
- Quark Pharmaceuticals
- RXi Pharmaceuticals
- Silence Therapeutics
- Benitec Biopharma
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed